Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome

Jules L. Derks, Noemie Leblay, Erik Thunnissen, Robert Jan Van Suylen, Michael den Bakker, Harry J. M. Groen, Egbert F. Smit, Ronald Damhuis, Esther C. van den Broek, Amelie Charbrier, Matthieu Foll, James D. McKay, Lynnette Fernandez-Cuesta, Ernst-Jan M. Speel, Anne-Marie C. Dingemans, PALGA Grp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)33-42
Number of pages10
JournalClinical Cancer Research
Volume24
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • MULTICENTER-PHASE-II
  • LUNG-CANCER
  • SURGICAL SPECIMENS
  • TUMORS
  • EXPRESSION
  • REPRODUCIBILITY
  • NEOPLASMS
  • CISPLATIN
  • FEATURES
  • THERAPY

Cite this

Derks, J. L., Leblay, N., Thunnissen, E., Van Suylen, R. J., den Bakker, M., Groen, H. J. M., Smit, E. F., Damhuis, R., van den Broek, E. C., Charbrier, A., Foll, M., McKay, J. D., Fernandez-Cuesta, L., Speel, E-J. M., Dingemans, A-M. C., & PALGA Grp (2018). Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome. Clinical Cancer Research, 24(1), 33-42. https://doi.org/10.1158/1078-0432.CCR-17-1921